Pfizer Inc. operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Pfizer Inc. with three other companies in this sector in the United States: Bayer AG (2018 sales of $46.64 billion of which 42% was Pharmaceuticals & Biological Products), Roche Holding Aktiengesellschaft ($58.19 billion of which 77% was Pharmaceuticals), and Novartis AG ($53.17 billion of which 66% was Innovative Medicines).

Sales Analysis. During the year ended December of 2018, sales at Pfizer Inc. were $53.65 billion. This is an increase of 2.1% versus 2017, when the company's sales were $52.55 billion. The sales level in 2018 was fairly close to the level five years ago: in 2013, Pfizer Inc. had sales of $51.58 billion. Sales of Operating Segment-Global Innovative Phar saw an increase that was more than double the company's growth rate: sales were up 6.4% in 2018, from $31.42 billion to $33.43 billion. Not all segments of Pfizer Inc. experienced an increase in sales in 2018: sales of Essential Health fell 4.3% to $20.22 billion.